These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 2697948)

  • 21. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
    Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
    Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies.
    Elms MJ; Bunce IH; Bundesen PG; Rylatt DB; Webber AJ; Masci PP; Whitaker AN
    Thromb Haemost; 1983 Aug; 50(2):591-4. PubMed ID: 6356456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects.
    Kim S; Wadhwa NK; Kant KS; Pollak VE; Glas-Greenwalt P; Weiss MA; Hong CG
    Q J Med; 1988 Nov; 69(259):879-905. PubMed ID: 3078212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of crosslinking on the structure of solubilized fibrin degradation products in whole plasma.
    Carroll RC; Lockhart MS; Taylor FB
    J Lab Clin Med; 1984 May; 103(5):695-703. PubMed ID: 6232329
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of static magnetic field on fibrinogen degradation products level in rabbits with thrombosis.
    Gorczyńska E
    J Hyg Epidemiol Microbiol Immunol; 1986; 30(3):269-73. PubMed ID: 3772089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Contribution of morphology to the identification of fibrinogen derivatives].
    Fabre J; Delsol G; Familiades J; Tapie C; Boneu B; Bierme R
    Pathol Biol (Paris); 1974 Nov; 22 suppl():53-9. PubMed ID: 4620096
    [No Abstract]   [Full Text] [Related]  

  • 27. Fibrinogen fragment D is necessary and sufficient to anchor a surface plasminogen-activating complex in Streptococcus pyogenes.
    Hess JL; Boyle MD
    Proteomics; 2006 Jan; 6(1):375-8. PubMed ID: 16287173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methods for correcting inhibitory effects of fibrinogen degradation products in fibrinogen determinations.
    Alving BM; Bell WR
    Thromb Res; 1976 Jul; 9(1):1-8. PubMed ID: 960061
    [No Abstract]   [Full Text] [Related]  

  • 29. Tests for hemostasis and their relevance to venous thrombosis.
    Johnston DW; Scott AA; Glynn MF
    Can J Surg; 1980 Jul; 23(4):373-80. PubMed ID: 6968239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinogen degradation products in fresh frozen plasma. Possible contribution to immunosuppression.
    Donnell CA; Daniel SJ; Ferrara JJ
    Am Surg; 1989 Aug; 55(8):505-7. PubMed ID: 2764399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Catabolism of purified rat fibrin(ogen) plasmin degradation products in rats.
    Nieuwenhuizen W; Emeis JJ; Vermond A
    Thromb Haemost; 1982 Aug; 48(1):59-61. PubMed ID: 7135343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mechanism of fibrinolysis (review of the literature)].
    Kovalenko AN
    Vrach Delo; 1983 Jan; (1):10-5. PubMed ID: 6223445
    [No Abstract]   [Full Text] [Related]  

  • 33. Platelet adhesion to fibrinogen, fibrin monomer, and fibrin protofibrils in flowing blood -- the effect of fibrinogen immobilization and fibrin formation.
    Jirousková M; Dyr JE; Suttnar J; Holada K; Trnková B
    Thromb Haemost; 1997 Sep; 78(3):1125-31. PubMed ID: 9308765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biological activity of fibrinogen derivatives].
    Kopeć M
    Pol Arch Med Wewn; 1978 Jan; 59(1):1-7. PubMed ID: 148641
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of the diagnostic performance of three soluble fibrin monomer tests and a D-dimer assay in patients with clinically suspected deep vein thrombosis of the lower limbs.
    Elias A; Cazanave G; Nguyen F; Elias M; Bongard V; Cambus JP
    Haematologica; 2004 Apr; 89(4):499-501. PubMed ID: 15075088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Plasminogen-binding centers of molecules of fibrinogen, fibrin and products of their proteolysis].
    Grinenko TV; Tret'iachenko VG; Kudinov SA; Medved' LV
    Biokhimiia; 1987 Oct; 52(10):1732-9. PubMed ID: 3427134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative study of various rapid methods of determining fibrinogen transformation products in the diagnosis of intravascular coagulation and fibrinolysis].
    Lychev VG; Momot AP; Cherkashin GV
    Ter Arkh; 1984; 56(6):106-9. PubMed ID: 6474366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered immunoelectrophoretic profiles of fibrinogen in full-term newborns.
    Kordich L; Bergonzelli G; Lago O; Sassetti B; Porterie P
    Thromb Res; 1986 Dec; 44(5):695-700. PubMed ID: 3810568
    [No Abstract]   [Full Text] [Related]  

  • 39. [Preventive effects of antithrombin Vi in experimental thrombogenesis].
    KUDRIASHOV BA; MOLCHANOVA LV; BAZAZ'IAN GG; KALISHEVSKAIA TM; SYTINA NP
    Vopr Med Khim; 1962; 8():69-72. PubMed ID: 14460206
    [No Abstract]   [Full Text] [Related]  

  • 40. [Relevance of fibrinogen/fibrin degradation products in the study of thrombosis].
    Páramo JA; Gaffney PJ
    Sangre (Barc); 1989 Dec; 34(6):497-501. PubMed ID: 2697948
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.